kyowa hakko

 

Topic mentions per year

Topic mentions per year

1998-2018
01219982018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
As part of our screening program to find new antitrypanosomal compounds, we evaluate isolates from soil-dwelling microorganisms… (More)
  • figure 1
  • table 1
Is this relevant?
Review
2010
Review
2010
IgA nephropathy (IgAN) is the most common form of glomerulonephritis and a principal cause of end-stage renal disease (ESRD… (More)
  • figure 1
Is this relevant?
2003
2003
Purpose: The purpose is to investigate the prophylactic effect of intravesically instillated recombinant IFNagainst recurrence of… (More)
  • table 2
  • table 1
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
2002
2002
The pyrazoloacridone, KW-2170, an alkylating agent and topoisomerase II inhibitor, is being developed by Kyowa Hakko Kogyo as a… (More)
Is this relevant?
1999
1999
GenCom, the first collaborative venture in Japan to concentrate on functional genomics, was created by Mitsubishi Chemical (Tokyo… (More)
Is this relevant?
1999
1999
  • Nature Biotechnology
  • 1999
GenCom, the first collaborative venture in Japan to concentrate on functional genomics, was created by Mitsubishi Chemical (Tokyo… (More)
Is this relevant?
1999
1999
GenCom, the first collaborative venture in Japan to concentrate on functional genomics, was created by Mitsubishi Chemical (Tokyo… (More)
Is this relevant?
1999
1999
GenCom, the first collaborative venture in Japan to concentrate on functional genomics, was created by Mitsubishi Chemical (Tokyo… (More)
Is this relevant?
1998
1998
Japan’s second clinical gene therapy trial began at Tokyo University’s Institute of Medical Sciences (IMS) on October 5th… (More)
Is this relevant?
1998
1998
Japan’s second clinical gene therapy trial began at Tokyo University’s Institute of Medical Sciences (IMS) on October 5th… (More)
Is this relevant?